# INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

Study · id `cardio:ct-nct02787044` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02787044](<https://clinicaltrials.gov/study/NCT02787044>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02787044

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5388 participants.

## Technical summary

Registry record NCT02787044. Randomized; quadruple masking; primary purpose prevention. Start 2016-08-01 (actual); primary completion 2020-05-31 (actual). Results posted on 2021-09-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 5388 participants (enrolled count; ClinicalTrials.gov record NCT02787044, source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)
- Started: 2016-08-01 (actual) (ClinicalTrials.gov record NCT02787044, source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)
- Primary completion: 2020-05-31 (actual) (ClinicalTrials.gov record NCT02787044, source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)
- Completion: 2020-05-31 (actual) (ClinicalTrials.gov record NCT02787044, source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)
- Results first posted: 2021-09-14 (ClinicalTrials.gov record NCT02787044, source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)
- Countries: United States; Canada; Puerto Rico (ClinicalTrials.gov record NCT02787044, source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02787044-2022-01-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
- Acronym: INVESTED
- Condition: Heart Failure
- Condition: Myocardial Infarction
- Intervention (Biological): High Dose Trivalent Influenza Vaccine
- Intervention (Biological): Standard Dose Quadrivalent Influenza Vaccine
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH
- Collaborator: University of Wisconsin, Madison
- Collaborator class: OTHER
- Collaborator: University of Toronto
- Collaborator class: OTHER
- Collaborator: Boston VA Research Institute, Inc.
- Collaborator class: OTHER
- Collaborator: Patient-Centered Outcomes Research Institute
- Collaborator class: OTHER
- Collaborator: University of Minnesota
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)
- Registry lists this organization as a collaborator: University of Wisconsin, Madison (`cardio:org-university-of-wisconsin-madison`)
- Registry lists this organization as a collaborator: University of Toronto (`cardio:org-university-of-toronto`)
- Registry lists this organization as a collaborator: Patient-Centered Outcomes Research Institute (`cardio:org-patient-centered-outcomes-research-institute`)
- Registry lists this organization as a collaborator: University of Minnesota (`cardio:org-university-of-minnesota`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial (`cardio:pubmed-33275134`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Temporal Association Among Influenza-Like Illness, Cardiovascular Events, and Vaccine Dose in Patients With High-Risk Cardiovascular Disease: Secondary Analysis of a Randomized Clinical Trial (`cardio:pubmed-37707817`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial (`cardio:pubmed-38583091`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Educational Attainment Level and Risk of Mortality and Cardiopulmonary Outcomes in High-Risk Patients With Cardiovascular Disease: The INVESTED Trial (`cardio:pubmed-40530474`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 658c467b38955800a4142f1b08c508b0b855be2f5482dad81dc5a931b2254478
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
